Adverse event documentation and reporting for clinics using biologics

Why adverse event documentation is part of a biologics program, not an afterthought

Any clinic that adds perinatal tissue or exosome products to its offerings should build an adverse event process before the first vial is used, not after a problem arises. This is distinct from clinical decision-making; it is a documentation and escalation discipline that applies regardless of the product category.

FDA has publicly warned that unapproved regenerative medicine products, including those derived from stem cells and exosomes, carry risks that consumers may not anticipate, and has separately warned about serious risks following use of unapproved products generally. Those warnings are directed at consumers, but they describe exactly the kind of event a clinic's internal process needs to be able to capture and route.

What belongs in an internal adverse event record

An internal record should be factual and contemporaneous: what was observed, when, by whom, and what was done in response. It should identify the product name, format, and lot number used, consistent with the lot-traceability record your clinic already keeps.

Keep factual observations and the treating clinician's assessment, including suspected product relationships, distinct from promotional claims. Confirm documentation and reporting requirements with counsel.

• Date and time of the event
• Patient identifier
• Product name, format, and lot number
• Description of what was observed, in objective terms
• Staff member who recorded the event
• Any follow-up action taken and its outcome

Reporting pathways: supplier, state board, and FDA

Your supplier should be notified of any adverse event associated with their product, since that notification contributes to the supplier's own lot-level surveillance. Separately, your state medical or nursing board may have its own reporting obligations tied to your license, which are independent of anything related to the product itself.

Whether a specific event meets a federal reporting threshold is a determination that depends on the product, the event, and current FDA guidance, and is best made with your own regulatory counsel rather than inferred from general information. This article does not constitute legal advice; clinics should confirm their reporting obligations directly with counsel familiar with HCT/P and biologic product regulation.

Why documentation quality matters beyond the individual event

FDA has cited distributor and clinic websites, social media, and affiliate content as evidence of a product's intended use in recent warning letters, which means the broader documentation trail around a product, not just clinical records, can become relevant if a product comes under scrutiny. A clinic with a thin, inconsistent, or missing adverse event record is in a weaker position to respond to any inquiry, regardless of its cause.

Treat your adverse event log the way you treat your lot-traceability log: as a standing operational record, maintained whether or not anything is actively happening, and reviewed periodically rather than only consulted in a crisis.

Training staff to recognize and record, not interpret

Define staff documentation and escalation roles with the clinical lead; preserve observations and clinician assessments without unsupported causal conclusions. That interpretation belongs to the treating clinician and, where appropriate, the clinic's medical director.

A short internal procedure, who records what, who reviews it, and how escalation to the supplier or a board happens, removes ambiguity at the moment an event occurs, which is when clarity matters most.